HER2 (Epidermal Growth Factor Receptor 2, HER2/neu, CD340) targeting via trastuzumab (Herceptin) or pertuzumab has demonstrated relatively good levels of success in breast cancer [5]. This evidence concerns the gene ERBB2 and breast carcinoma.